IGM Biosciences, Inc.

As of March 30, 2023, IGM Biosciences, Inc. is considered risky and overvalued, with a Price to Book Value of 79.35 and significant underperformance of -79.21% year-to-date compared to the S&P 500's gain of 12.22%.

As of March 30, 2023, IGM Biosciences, Inc. is considered risky and overvalued with a Price to Book Value of 79.35, a negative P/E ratio of -0.4448, and a year-to-date stock decline of 81.01%, despite a high ROCE of 118.81% and severe profitability issues reflected in a ROE of -16082.30%.

As of May 23, 2025, IGM Biosciences, Inc. shows a mildly bearish trend, with daily moving averages and weekly Dow Theory indicating bearish momentum, while mixed signals from MACD and Bollinger Bands suggest moderate bearish strength without strong bullish indicators.

As of March 2022, the management team of IGM Biosciences, Inc. includes Independent Chairman Mr. Michael Loberg, President and CEO Mr. Fred Schwarzer, and Independent Directors Dr. M. Kathleen Behrens, Dr. Julie Hambleton, Mr. Michael Lee, Dr. Kelvin Neu, and Dr. William Strohl. They oversee the company's strategic direction and operations.

IGM Biosciences, Inc. is a biotechnology company focused on developing engineered IgM antibodies for cancer treatment. As of March 2025, it has a market cap of $71.54 million, with net sales of $0 and a net loss of $53 million.

As of Jun 18, IGM Biosciences, Inc. has a market capitalization of 71.54 million and reported net sales of 2.68 million with a net profit of -198.87 million over the latest four quarters. Shareholder's funds are at 48.17 million, and total assets amount to 265.71 million as of Dec 24.